Tofflon Science and Technology Group Co., Ltd.'s (SZSE:300171) Share Price Is Matching Sentiment Around Its Revenues
I'm LongbridgeAI, I can summarize articles.Tofflon Science and Technology Group Co., Ltd. (SZSE:300171) has a low price-to-sales (P/S) ratio of 2.1x, compared to the industry average of 6.4x, making it appear attractive. However, the company's revenue has declined by 20% recently, leading to a pessimistic outlook among investors. Analysts forecast a modest revenue growth of 5.8% for the next year, significantly lower than the industry average of 23%. This underperformance contributes to the low P/S ratio, and unless conditions improve, the share price is likely to remain stagnant.
When close to half the companies in the Medical Equipment industry in China have price-to-sales ratios (or "P/S") above 6.4x, you may consider Tofflon Science and Technology Group Co., Ltd. (SZSE:300171) as a highly attractive investment with its 2.1x P/S ratio. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.
Check out our latest analysis for Tofflon Science and Technology Group
How Has Tofflon Science and Technology Group Performed Recently?
While the industry has experienced revenue growth lately, Tofflon Science and Technology Group's revenue has gone into reverse gear, which is not great. It seems that many are expecting the poor revenue performance to persist, which has repressed the P/S ratio. So while you could say the stock is cheap, investors will be looking for improvement before they see it as good value.
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Tofflon Science and Technology Group.
Do Revenue Forecasts Match The Low P/S Ratio?
There's an inherent assumption that a company should far underperform the industry for P/S ratios like Tofflon Science and Technology Group's to be considered reasonable.
In reviewing the last year of financials, we were disheartened to see the company's revenues fell to the tune of 20%. Regardless, revenue has managed to lift by a handy 29% in aggregate from three years ago, thanks to the earlier period of growth. Accordingly, while they would have preferred to keep the run going, shareholders would be roughly satisfied with the medium-term rates of revenue growth.
Shifting to the future, estimates from the sole analyst covering the company suggest revenue should grow by 5.8% over the next year. Meanwhile, the rest of the industry is forecast to expand by 23%, which is noticeably more attractive.
With this in consideration, its clear as to why Tofflon Science and Technology Group's P/S is falling short industry peers. Apparently many shareholders weren't comfortable holding on while the company is potentially eyeing a less prosperous future.
The Final Word
Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.
As expected, our analysis of Tofflon Science and Technology Group's analyst forecasts confirms that the company's underwhelming revenue outlook is a major contributor to its low P/S. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.
Don't forget that there may be other risks. For instance, we've identified 3 warning signs for Tofflon Science and Technology Group (1 is a bit unpleasant) you should be aware of.
If strong companies turning a profit tickle your fancy, then you'll want to check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).